Litcius/Paper detail

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited

Philippe Gautret, Jean‐Christophe Lagier, Stéphane Honoré, Van Thuan Hoang, Philippe Colson, Didier Raoult

2021International Journal of Antimicrobial Agents49 citationsDOIOpen Access PDF

Topics & Concepts

AzithromycinHydroxychloroquineCoronavirus disease 2019 (COVID-19)MedicineRandomized controlled trialOpen label2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyInternal medicineAntibioticsMicrobiologyBiologyOutbreakInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesDrug-Induced Ocular ToxicityPharmacological Receptor Mechanisms and Effects
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited | Litcius